Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope
Overview
Affiliations
The Gibbon Ape Leukemia Virus envelope protein (GALV-Env) mediates efficient transduction of human cells, particularly primary B and T lymphocytes, and is therefore of great interest in gene therapy. Using internal domains from murine leukemia viruses (MLV), chimeric GALV-Env proteins such as GALV-C were derived, which allow pseudotyping of lentiviral vectors. In order to improve expression efficiency and vector titers, we developed a codon-optimized (co) variant of GALV-C (coGALV-Env). We found that coGALV-Env mediated efficient pseudotyping not only of γ-retroviral and lentiviral vectors, but also α-retroviral vectors. The obtained titers on HEK293T cells were equal to those with the classical GALV-Env, whereas the required plasmid amounts for transient vector production were significantly lower, namely, 20 ng coGALV-Env plasmid per 10 293T producer cells. Importantly, coGALV-Env-pseudotyped γ- and α-retroviral, as well as lentiviral vectors, mediated efficient transduction of primary human T cells. We propose that the novel chimeric coGALV-Env gene will be very useful for the efficient production of high-titer vector preparations, e.g., to equip human T cells with novel specificities using transgenic TCRs or CARs. The considerably lower amount of plasmid needed might also result in a significant cost advantage for good manufacturing practice (GMP) vector production based on transient transfection.
Molecular Engineering of Virus Tropism.
He B, Wilson B, Chen S, Sharma K, Scappini E, Cook M Int J Mol Sci. 2024; 25(20).
PMID: 39456875 PMC: 11508178. DOI: 10.3390/ijms252011094.
Jargalsaikhan B, Muto M, Been Y, Matsumoto S, Okamura E, Takahashi T Viruses. 2024; 16(6).
PMID: 38932120 PMC: 11209056. DOI: 10.3390/v16060827.
Renner A, Stahringer A, Ruppel K, Fricke S, Koehl U, Schmiedel D Gene Ther. 2024; 31(7-8):378-390.
PMID: 38684788 PMC: 11257948. DOI: 10.1038/s41434-024-00454-0.
Harfmann M, Schroder T, Glow D, Jung M, Uhde A, Kroger N Cancers (Basel). 2024; 16(2).
PMID: 38254824 PMC: 10814116. DOI: 10.3390/cancers16020334.